About the Company
Johnson and Johnson (J&J) is a multinational company, which manufactures and sells pharmaceutical products, medical devices and consumer packaged commodities. The company has more than 250 subsidiaries and operates in approximately 60 countries worldwide. Johnson and Johnson shares are traded on the New York Stock Exchange (NYSE) under the ticker symbol “JNJ”.
Some of its consumer commodities include baby care, skincare, and oral care products. Few of the most noteworthy products are Band-Aid, Clean and Clear face wash, Neutrogena skin care and beauty products, etc. The medical devices segment involves the production and sale of various products that are used in fields related to healthcare, such as orthopaedic, surgical and vision care. The pharmaceutical segment involves the development of medicines that are focused on treating infectious, metabolic and cardiovascular diseases. It also manufactures medicines for oncology and neuroscience divisions.
JNJ research facilities are located in various countries worldwide; some of them include Brazil, France, India, China, Canada and Japan. JNJ was founded in 1886 and started operations with a team of 14 employees. They manufactured household commodities and surgical supplies and sterile instruments that used to have a logo resembling the signature of one of the co-founders, James Wood Johnson. JNJ made history when it became the first company in the world to produce sterile surgical products like gauze and absorbent cotton.
In 1921, JNJ launched Johnson’s Baby Soap, and ten years later, it started manufacturing and selling the first prescription contractive gel under the name Ortho-Gynol. Some of the notable subsidiaries of JNJ include Janssen Pharmaceutica, Neutrogena, Biosense Webster, Janssen Biotech, Ortho-McNeil Pharmaceutical, Animas Corporation and Advanced Sterilization Products Services, Inc.
Since its inception, JNJ has acquired more than 40 companies out of which 9 were private equity firms. In 1998, it acquired DePuy, which further strengthened its medical devices segment. In 2012, JNJ announced the acquisition of Synthes for an estimated $19.7 billion. Two years later, in 2014, Alios BioPharma was acquired by JNJ for $1.75 billion. It completed its largest acquisition in 2017 when it acquired Actelion Pharmaceuticals Ltd. for approximately $30 billion. JNJ has made acquisitions in more than ten states in America and over five countries worldwide.
In 2019, JNJ announced that one of its subsidiaries, Ethicon, had reached an agreement to acquire Auris Health, Inc. The acquisition was completed for $3.4 billion in cash and involved $2.3 billion worth of contingent payments based on future performance. In August 2020, it announced that it would be acquiring Momenta Pharmaceuticals for approximately 6.5 million. In 2014, JNJ disclosed its largest sale, when it sold its Ortho-Clinical Diagnostics to the Carlyle Group for over $4 billion.
In 2020, JNJ received the Best Leadership Teams 2020 award. In the same year, JNJ ranked 34th on the Forbes’ list of the world’s 2,000 largest public companies. It also occupied the 35th spot on the list of the Fortune 500 companies in 2020.;
|Organisation||Johnson & Johnson|
|HeadQuarters||New Brunswick, NJ|